Pharmaceutical News

RSS

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Titan Pharmaceuticals, Inc today announced that Vanda Pharmaceuticals, Inc. reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanapt™ (iloperidone) in the U.S. and Canada. Fanapt™, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults.

13 Oct 2009

New guidelines for treating amyotropic lateral sclerosis

Dr. John England, Professor and Chairman of Neurology at LSU Health Sciences Center New Orleans, analyzed research findings and was responsible for the quality and accuracy of evidence analysis and the conclusions of the studies resulting in new guidelines for treating Lou Gehrig's disease, or amyotropic lateral sclerosis (ALS).

13 Oct 2009

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute.

13 Oct 2009

Cox's initiative to safeguard the community at-large

Recognized as a leader in serving its customers with state-of-the-art cable, broadband and entertainment services, Cox will soon broaden its local impact by safeguarding the community at-large. On October 30, 2009, Cox will be the first and only private corporation to operate as one of three Orange County locations to conduct an Orange County Health Care Agency (OCHCA) Point-Of-Dispensing (POD) at its Rancho Santa Margarita headquarters.

13 Oct 2009

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.

13 Oct 2009

Educational video on seasonal and H1N1 vaccines development

Will a four-minute educational video about a team of Air Force researchers investigating the H1N1 influenza virus go "viral" with middle- and high-school students?

12 Oct 2009

Low-, middle-income countries could receive donated H1N1 vaccine shipments by November, WHO says

About 100 low- and middle-income countries could receive donated shipments of the H1N1 (swine flu) vaccine as early as November, Marie-Paule Kieny, of the WHO, told journalists Monday, Agence France-Presse reports. "Dozens of millions of doses are being lined up following offers from pharmaceutical companies," including Sanofi-Aventis, GlaxoSmithKline and MedImmune, as well as a coalition of developed nations "that have pledged to release 10 percent of their vaccine purchases for poor nations," the news service writes (10/12).

12 Oct 2009

Some scientists question results of recent HIV vaccine clinical trial

Weeks after clinical trial results showed an experimental HIV vaccine offered some potential protection against the virus, "a second analysis of the $105 million study, not disclosed publicly, suggests the results may have been a fluke, according to AIDS scientists who have seen it," the Wall Street Journal reports.

12 Oct 2009

Even with early shortages, public is conflicted about getting the swine flu vaccine

A federal health official downplays risks from swine flu vaccine while the demand for the vaccine causes shortages.

12 Oct 2009

B. Braun Medical announces agreement with HealthTrust to provide pain management products

B. Braun Medical Inc. (B. Braun) has announced an expanded agreement with HealthTrust Purchasing Group (HealthTrust) to provide pain management products to HealthTrust's membership.

From B. Braun Melsungen AG 12 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

Z-Medica launches QuikClot Trauma Pad

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced the availability of the QuikClot® Trauma Pad™ hemostatic dressing, on display at booth #1721 at the American College of Surgeons 95th Annual Clinical Congress. The new QuikClot Trauma Pad’s 12 x 12 inch size makes it well-suited to control bleeding from large traumatic wounds.

From Medica Corporation 12 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

Communications technology for students and employees to manage their healthcare relationships

Allviant Corporation today announced the launch of its CarePass™ pilot program with Arizona State University to add another tool to the university’s health and wellness communications and services while empowering its employees and students with tools to manage their healthcare relationships.

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Santarus, Inc., a specialty biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, today announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID® products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe.

12 Oct 2009

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.

12 Oct 2009

Pieris reports its progress in the development of PRS-050

Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.

12 Oct 2009

PPA bus tour to raise awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Iowa, Southern Illinois, and Southern Indiana throughout the week of October 12 -- 16th at various cities in order to help uninsured and financially-struggling Midwesterners access information on programs that provide prescription medicines for free or nearly free.

12 Oct 2009

FDA approves Berinert for the treatment of hereditary angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

12 Oct 2009

Pharmaceutical News

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

New guidelines for treating amyotropic lateral sclerosis

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

Cox's initiative to safeguard the community at-large

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

Educational video on seasonal and H1N1 vaccines development

Low-, middle-income countries could receive donated H1N1 vaccine shipments by November, WHO says

Some scientists question results of recent HIV vaccine clinical trial

Even with early shortages, public is conflicted about getting the swine flu vaccine

B. Braun Medical announces agreement with HealthTrust to provide pain management products

QRxPharma signs contractual agreement with Patheon

Z-Medica launches QuikClot Trauma Pad

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

Communications technology for students and employees to manage their healthcare relationships

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Pieris reports its progress in the development of PRS-050

PPA bus tour to raise awareness of patient assistance programs

FDA approves Berinert for the treatment of hereditary angioedema

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News